In particular, the BRAF V600E point mutation is the most frequent alteration in papillary thyroid cancers (PTC) (45–60%); RAS and then TERT promoter point mutations can be also found and gene fusions (TRK 1/3, RET, ALK, BRAF) are detectable in only 15% of tumor samples [28]. Here, BRAF is linked to neoplasm.